Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00370565 · ClinicalTrials.gov registry record · Phase 3
Effect on Glycemic Control of Inhaled Insulin Alone or Added to Dual Oral Therapy After Failure of Dual Oral Therapy.
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 345
- Enrollment target
NCT00370565: Completed Phase 3 study, sponsored by Pfizer.
NCT00370565 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 345 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00370565, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 345 participants
- Enrollment target
Study Summary
To assess the impact on glucose control by inhaled insulin alone or added to two oral anti-diabetic agents in patients with type 2 diabetes who are not well controlled on 2 oral anti-diabetic agents.
Interventions
- DRUG Inhaled Human Insulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 345 participants |
| Start Date | 1999-06 |
| Est. Completion | 2000-09 |
| Phase | Phase 3 |
What the finished NCT00370565 record still lists
NCT00370565 is an interventional study that assigns participants to a tested intervention. The registered 345 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 1 intervention - of which Inhaled Human Insulin is the first listed.
NCT00370565 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00370565 about?
NCT00370565 is a clinical study titled "Effect on Glycemic Control of Inhaled Insulin Alone or Added to Dual Oral Therapy After Failure of Dual Oral Therapy.". To assess the impact on glucose control by inhaled insulin alone or added to two oral anti-diabetic agents in patients with type 2 diabetes who are not well controlled on 2 oral anti-diabetic agents.
What is the current status of trial NCT00370565?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 345 participants. The study started on 1999-06. Estimated completion is 2000-09.
What interventions are being tested in trial NCT00370565?
The interventions under investigation include: Inhaled Human Insulin (DRUG).
Who is sponsoring clinical trial NCT00370565?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00370565's enrollment target sits among peer trials
345 1050th of 2000 higher than 951 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03972657 · 345 participants · Phase 1
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
- NCT05107674 · 345 participants · Phase 1
A Study of NX-1607 in Adults With Advanced Malignancies
- NCT05700279 · 345 participants · NA
Preventing the Development of Chronic Pain: Treating PTSD at Acute Pain Onset
- NCT05781100 · 345 participants · NA
Investigating Baby Behavior and Family Technology Use Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia